<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01591850</url>
  </required_header>
  <id_info>
    <org_study_id>BP27852</org_study_id>
    <nct_id>NCT01591850</nct_id>
  </id_info>
  <brief_title>A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Single-center, Open-label, One-sequence, Two-period Crossover Study in 3 Parts to Investigate the Effects of Multiple Doses of Ketoconazole (Part 1), Rifampicin (Part 2), and Ritonavir-boosted Atazanavir (Part 3) on the PK of a Single Dose of RO5093151 in Healthy Female &amp; Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This randomized, single-center, open-label, one-sequence, two-period crossover study in three
      parts will assess the effects of multiple doses of ketoconazole, rifampicin and
      ritonavir-boosted atazanavir on the pharmacokinetics of a single dose of RO5093151 in healthy
      male and female volunteers. In Period 1, subjects will receive a single oral dose of
      RO5093151. In Period 2, subjects will receive a single oral dose of RO5093151 and multiple
      oral doses of either ketoconazole, rifampicin or ritonavir-boosted atazanavir. Anticipated
      time on study is up to 8.5 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Effect of multiple doses of ketoconazole on single-dose pharmacokinetics of RO5093151 and metabolites: Area under the concentration-time curve (AUC)</measure>
    <time_frame>Pre-dose and up to 72 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Effect of multiple doses of rifampicin on single-dose pharmacokinetics of RO5093151 and metabolites: Area under the concentration-time curve (AUC)</measure>
    <time_frame>Pre-dose and up to 72 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Effect of multiple doses of ritonavir-boosted atazanavir on single-dose pharmacokinetics of RO5093151 and metabolites: Area under the concentration-time curve (AUC)</measure>
    <time_frame>Pre-dose and up to 72 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RO5093151 metabolites: Plasma/urine concentrations</measure>
    <time_frame>Pre-dose and up to 72 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Area under the effect curve (AUEC) for plasma cortisol/cortisone (Part 1 only)</measure>
    <time_frame>Pre-dose and up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>1 Ketoconazole DDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Rifampicin DDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3 ATZ/r DDI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5093151</intervention_name>
    <description>Single oral dose</description>
    <arm_group_label>1 Ketoconazole DDI</arm_group_label>
    <arm_group_label>2 Rifampicin DDI</arm_group_label>
    <arm_group_label>3 ATZ/r DDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atazanavir</intervention_name>
    <description>Multiple oral doses</description>
    <arm_group_label>3 ATZ/r DDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketoconazole</intervention_name>
    <description>Multiple oral doses</description>
    <arm_group_label>1 Ketoconazole DDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifampicin</intervention_name>
    <description>Multiple oral doses</description>
    <arm_group_label>2 Rifampicin DDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <description>Multiple oral doses</description>
    <arm_group_label>3 ATZ/r DDI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects, 18 to 65 years of age. Healthy status is defined by
             absence of evidence of any active or chronic disease following a detailed medical and
             surgical history and complete physical examination

          -  Body mass index (BMI) 18 to 30 kg/m2

          -  Females of child-bearing potential must agree to use two effective methods of
             contraception, including a barrier method and an intrauterine non-hormonal device (set
             in place at least 3 months before first dosing) for the duration of the study and at
             least 1 month after last dosing

          -  Non-smoker for at least 90 days prior to screening

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  History of drug abuse in the past 2 years, or suspicion of regular consumption of
             drugs of abuse, or positive result on drugs of abuse test

          -  History of alcoholism in the past 2 years, or positive alcohol test

          -  Positive for hepatitis B, hepatitis C or HIV infection

          -  Systemic , topical, intranasal or inhaled corticosteroid therapy for more than 2 weeks
             within 3 months prior to screening

          -  Participation in an investigational drug or device study within 90 days prior to
             screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Merritt Island</city>
        <state>Florida</state>
        <zip>32953</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2012</study_first_submitted>
  <study_first_submitted_qc>May 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2012</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

